Repros Therapeutics Inc., of The Woodlands, Texas, said it fully randomized a phase II double-blind, placebo-controlled proof-of-concept study of enclomiphene, an estrogen receptor antagonist, in conjunction with rigorous diet and exercise in the treatment of obese secondary hypogonadal men. The study enrolled its target of 45 subjects, and top-line interim results for three months and six months are expected this summer.